Display Settings:

Format
Sort by

Send to:

Choose Destination

Results: 5

1.

Monitoring the Dynamics of T Cell Clonal Diversity Using Recombinant Peptide:MHC Technology.

Blanchfield JL, Shorter SK, Evavold BD.

Front Immunol. 2013 Jul 3;4:170. doi: 10.3389/fimmu.2013.00170. eCollection 2013.

PMID:
23840195
[PubMed]
Free PMC Article
2.

Cytokine-neuroantigen fusion proteins as a new class of tolerogenic, therapeutic vaccines for treatment of inflammatory demyelinating disease in rodent models of multiple sclerosis.

Mannie MD, Blanchfield JL, Islam SM, Abbott DJ.

Front Immunol. 2012 Aug 20;3:255. doi: 10.3389/fimmu.2012.00255. eCollection 2012.

PMID:
22934095
[PubMed]
Free PMC Article
3.

Neuroantigen-specific, tolerogenic vaccines: GM-CSF is a fusion partner that facilitates tolerance rather than immunity to dominant self-epitopes of myelin in murine models of experimental autoimmune encephalomyelitis (EAE).

Abbott DJ, Blanchfield JL, Martinson DA, Russell SC, Taslim N, Curtis AD, Mannie MD.

BMC Immunol. 2011 Dec 30;12:72. doi: 10.1186/1471-2172-12-72.

PMID:
22208499
[PubMed - indexed for MEDLINE]
Free PMC Article
4.
5.

Experimental autoimmune encephalomyelitis in Lewis rats: IFN-beta acts as a tolerogenic adjuvant for induction of neuroantigen-dependent tolerance.

Mannie MD, Abbott DJ, Blanchfield JL.

J Immunol. 2009 May 1;182(9):5331-41. doi: 10.4049/jimmunol.0803756.

PMID:
19380780
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk